First reported by ft.com
AstraZeneca shares slide 9% after heart treatment disappoints in trial
AstraZeneca sees stock market value slump by more than £20bn after drug setback
From the article
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Continue reading on The IndependentYou might also wanna read
AstraZeneca sees stock market value slump by more than £20bn after drug setback
ireland-live.ie·4h ago
AstraZeneca shares slide 9% after heart treatment disappoints in trial
ft.com·7h ago
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Astrazeneca's stock dropped 9.1% after disappointing Phase 3 trial results for its heart drug Wainua. Over 140 weeks, the drug failed to sta
finans.dk·6h agoAstraZeneca loses £20bn in value after major heart drug trial setback
Londonlovesbusiness·3h ago
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
thehindubusinessline.com·7h ago
Dividenden-Garant Astrazeneca im freien Fall: Studien-Flop schockt Anleger
aktiencheck.de
Comments
Sign in to join the conversation.
No comments yet. Be the first.